Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

Video

In Partnership With:

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Despite success, there are several questions that remain. One crucial area, Wolchok says, is the need identify biomarkers to enrich patient populations.

Research is also focusing on how to form rational, potent, and safe combinations of immunotherapies. Wolchok says research is also being conducted looking at combining immunotherapies and targeted therapies. This area is particularly important, as some targeted pathway inhibitors could have a positive or negative effect on immune cells, in addition to having activity against cancer cells.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD